top of page
  • LinkedIn
  • Facebook

Discover the Vertuco difference. With our extensive experience, we can help you develop a successful strategy for your business.

We provide high-quality consulting with a personal touch to be sure that exactly what you need is delivered in an efficient and effective manner.

We help a pharmaceutical business grow.

Who are we

About

About us

Vertuco is a boutique consulting services company that provides high-quality services in regulatory compliance, quality systems, and project management. We help our customers improve the quality of their products and processes while working toward regulatory compliance.

Our dedicated team of professionals is up to the task of handling even the most complex regulatory needs. We provide guidance on how to meet today's strict FDA requirements while maintaining a competitive edge.

We assist our customers through every step of their product lifecycle - from planning, design, development, and manufacturing to marketing and distribution. We offer complete solutions that help you avoid costly mistakes, reduce risk, increase quality & efficiency, and drive revenue growth.

Vertuco Pharmaceutical Consultancy_edited.jpg

Services

Vertuco delivers a range of services to help your pharmaceutical business achieve its goals and objectives. Our focus is on quality management systems and projects that have a critical impact on customer business and sustainability such as GxP Audits, GxP training, Project management, Outsourcing, Consultancy, and Qualification. We work with our clients from inception through execution, ensuring that the solution is tailored to each individual company's needs.

Projects

News

Exciting New Progress in Hepatocellular Treatment with SGN1: Guangzhou 
Sinogen’s Clinical Trials 

Guangzhou Sinogen Pharmaceutical (also known as “Hua Jin”) is proud to announce 
the ongoing progress in our clinical trials for hepatocellular carcinoma (HCC) with 
our innovative biological drug, SGN1. This innovative drug is at the forefront of our 
efforts to address significant unmet medical needs in cancer treatment. Multiple 
hospitals across mainland China, China Taiwan, and the US are actively participating 
in our trials. 
We are pleased to report some encouraging results from the ongoing IND trials and an 
investigator-initiated (IIT) clinical study, where a total of 6 HCC recurrent patients 
who have received at least two lines of SOC were enrolled. One patient achieved 
Complete Response (CR), and two achieved Partial Response (PR), with survival 
times of 50 months, 11 months, and 6.5 months, respectively. In addition, one patient 
whose HCC lesion achieved stable (SD) condition, and is still receiving ongoing 
treatment with an expected PFS duration of at least 10 months. To put this in 
perspective, the median survival for HCC patients after failing second-line treatments 
is typically 8-12 months. These results reflect the potential of SGN1 to improve 
patient outcomes significantly. 
Guangzhou Sinogen remains dedicated to developing first-in-class therapies for HCC 
and other aggressive malignancies. Stay tuned for further updates as we advance our 
Phase IIa trials for both HCC, pancreatic cancer, and sarcoma.

Contact

CONTACT

Thanks for submitting!

Woman Typing

Join our mailing list

Thanks for submitting!

© 2023 by VERTUCO Ltd

bottom of page